T. de Pas

发表

Gemcitabine-induced systemic capillary leak syndrome.

L. Spaggiari, G. Curigliano, F. de Braud, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial

Michael Thomas, Armando Santoro, Martin Schuler, 2016, The Lancet. Oncology.

Prophylaxis for venous thromboembolism in cancer patients with a central vein catheter: new tones for an old song.

A. Goldhirsch, F. D. De Braud, G. Curigliano, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19

P. Queirolo, C. Jemos, E. Omodeo Salè, 2020, Seminars in Oncology.

Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinoma.

F. Orsi, F. D. De Braud, G. Curigliano, 2003, Anticancer research.

Boosting anticancer immunotherapy through androgen receptor blockade.

F. Conforti, L. Pala, T. de Pas, 2022, Cancer cell.

Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials

G. Giaccone, P. Queirolo, V. Bagnardi, 2021, ESMO open.

Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005.

A. Bottomley, A. Shaw, T. Mok, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non-small cell lung cancer (NSCLC).

S. Barni, S. Novello, F. de Marinis, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development.

A. Goldhirsch, F. D. De Braud, G. Curigliano, 2008, European journal of cancer.

Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study

Robin L. Jones, J. Blay, O. Mir, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Primary and recurrent retroperitoneal soft tissue sarcoma: Prognostic factors affecting survival

A. Testori, A. Zbar, E. Bertani, 2006, Journal of surgical oncology.

Sex Differences in Efficacy and Toxicity of Systemic Cancer Treatments: Role of the Microbiome.

A. Goldhirsch, L. Nezi, P. Ferrucci, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials

G. Giaccone, F. Conforti, L. Pala, 2022, Expert Opinion on Investigational Drugs.

Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.

A. Chella, A. Santoro, M. Tiseo, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The sacral chordoma margin.

P. Georg, P. Navarria, D. Campanacci, 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Intracavitary chemotherapy with thiotepa in malignant pericardial effusions: an active and well-tolerated regimen.

A. Goldhirsch, A. Gallino, G. Martinelli, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pulsed Dose-Rate Perioperative Interstitial Brachytherapy for Soft Tissue Sarcomas of the Extremities and Skeletal Muscles of the Trunk

L. Mariani, G. Pelosi, A. Testori, 2005, Annals of Surgical Oncology.

Friedreich's ataxia and intrathecal chemotherapy in a patient with lymphoblastic lymphoma.

A. Goldhirsch, F. D. De Braud, M. Aapro, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Factor v leiden mutation in patients with breast cancer with a central venous catheter: risk of deep vein thrombosis.

F. Orsi, A. Goldhirsch, F. D. De Braud, 2006, Supportive cancer therapy.

Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials

G. Giaccone, R. Gelber, C. Specchia, 2022, JAMA Network Open.

Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME).

V. Torri, M. Scorsetti, G. Apolone, 2018, Cancer treatment reviews.

1173OMAGRIT, A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF THE RECMAGE-A3 + AS15 CANCER IMMUNOTHERAPEUTIC AS ADJUVANT THERAPY IN PATIENTS WITH RESECTED MAGE-A3-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC).

N. Altorki, P. Therasse, T. Mitsudomi, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Optimizing Clinical Care in Patients with Advanced Soft Tissue Sarcoma: A Phase II Study of a New Schedule of High-Dose Continuous Infusion Ifosfamide and Doxorubicin Combination

D. Radice, C. Boni, T. De Pas, 2011, Chemotherapy.

Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas.

C. Boni, G. Curigliano, O. Pagani, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?

A. Goldhirsch, M. Aapro, N. Fazio, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study

C. Gridelli, S. Thongprasert, E. Felip, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil.

M. Aapro, F. Debraud, E. Munzone, 1998, American journal of clinical oncology.

1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Sarcoma of the breast: outcome and reconstructive options.

A. Luini, P. Veronesi, E. Marrazzo, 2012, Clinical breast cancer.

A phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors (GISTs) resistant to imatinib mesylate.

F. D. De Braud, H. Joensuu, P. Casali, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature.

G. Curigliano, P. Queirolo, P. Tarantino, 2020, Cancer treatment reviews.

1295PEFFICACY AND SAFETY OF CERITINIB IN PATIENTS (PTS) WITH ADVANCED ANAPLASTIC LYMPHOMA KINASE (ALK)-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC): AN UPDATE OF ASCEND-1.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Preoperative chemotherapy in non-small-cell lung cancer: nothing new in N2 disease.

U. Pastorino, L. Spaggiari, F. D. De Braud, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations.

R. Gelber, M. Buyse, M. Piccart, 2022, JAMA oncology.

Induction chemoradiotherapy for superior sulcus non-small-cell lung cancer: an answer for few.

F. Petrella, P. Solli, G. Veronesi, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy.

G. Curigliano, P. Queirolo, P. Ferrucci, 2022, European journal of cancer.

Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer.

G. Curigliano, R. Danesi, S. Fogli, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

M. Socinski, R. Govindan, A. Shaw, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunotherapy of advanced renal cell carcinoma

F. D. De Braud, M. Maffezzini, T. de Pas, 1996 .

Under-representation of women in Randomized Clinical Trials testing anticancer immunotherapy may undermine female patients care. A call to action.

F. Conforti, L. Pala, T. de Pas, 2022, Seminars in oncology.

An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer.

Umberto Ricardi, Suresh Senan, Giulio Melloni, 2014, Clinical lung cancer.

A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients.

L. Spaggiari, F. D. De Braud, G. Curigliano, 2006, Lung cancer.

Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a post-hoc analysis

F. Grosso, P. Casali, S. Ferrari, 2022, Frontiers in Oncology.

Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options.

A. Delmonte, M. Santarpia, M. Barberis, 2014, Critical reviews in oncology/hematology.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Michael Thomas, Takashi Seto, Kazuhiko Nakagawa, 2013, The New England journal of medicine.

Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases.

A. Luini, F. D. De Braud, A. Testori, 2008, Critical reviews in oncology/hematology.

Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.

P. Solli, G. Veronesi, L. Spaggiari, 2012, Critical reviews in oncology/hematology.

Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study

T. De Pas, J. Pujol, M. Debois, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Review Article: Pulmonary Sarcomatoid Carcinomas: A Practical Overview

G. Pelosi, D. Galetta, G. Veronesi, 2010, International journal of surgical pathology.

Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?

A. Testori, F. Verrecchia, G. Mazzarol, 2012, Clinical & Experimental Metastasis.

Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer

F. D. De Braud, G. Curigliano, R. Danesi, 2003, Pharmacological Reviews.

Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence

R. Gelber, A. Goldhirsch, G. Viale, 2019, Breast Cancer Research.

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.

R. Gelber, A. Goldhirsch, G. Viale, 2018, The Lancet. Oncology.

Thymic epithelial tumors: From biology to treatment.

G. Giaccone, F. Conforti, L. Pala, 2020, Cancer treatment reviews.

Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion

G. Giaccone, R. Gelber, C. Swanton, 2021, Clinical Cancer Research.

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

D. Planchard, P. Jänne, M. Ahn, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant chemotherapy in new stage II pN0 non-small cell lung cancer: a new issue for a case-by-case decision making process.

G. Veronesi, F. D. De Braud, T. De Pas, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2‐B3) and thymic carcinoma previously treated with chemotherapy

A. Santoro, S. Bozzarelli, L. Giordano, 2021, Cancer.

Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.

Yi-Song Wang, G. Giaccone, Justine N. McCutcheon, 2017, Cancer research.

Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E

F. de Marinis, L. Preda, M. Barberis, 2014, OncoTargets and therapy.

Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group.

G. Curigliano, G. Lo Russo, P. Zucali, 2022, European journal of cancer.

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.

S. Barni, V. Torri, S. Novello, 2014, The Lancet. Oncology.

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.

Moon Soo Kim, N. Altorki, P. Therasse, 2016, The Lancet. Oncology.

Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura.

G. Pelosi, F. D. De Braud, T. De Pas, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

J. Engelman, Michael Thomas, A. Shaw, 2014, The New England journal of medicine.

Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?

E. Giovannetti, G. Peters, F. Toffalorio, 2012, Pharmacogenomics.

Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study

H. Joensuu, P. Casali, C. Spreafico, 2011, British Journal of Cancer.